Xencor, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing engineered antibody candidates for cancer, autoimmune disease and inflammatory disease. Its Form 8-K disclosures cover financial results, Regulation FD presentations for XmAb942, XmAb412 and the TL1A portfolio, royalty-related disclosures for Ultomiris, and material developments involving collaboration and license agreements.
Proxy materials describe board elections, executive compensation, equity-award information, stockholder voting matters and governance policies. Additional current reports address compensatory arrangements, including executive severance policy disclosures, alongside capital resources and operating-runway information furnished with financial updates.